Regulatory
InflaRx reported financial and operating results for the first quarter ended March 31, 2019.
Medtronic plc announced financial results for its fiscal year and fourth quarter 2019, which ended April 26, 2019.
FDA Chief of Staff Lauren Silvis indicated the FDA is “pushing forward” with its nonprescription safe use regulatory expansion (NSURE) program, and that “OTC monograph reform remains a top priority for the agency” but “it’s up to Congress to legislate the issue.”
Promore Pharma’s most important task is to develop new products aiming to improve the quality of life for patients with difficult-to-treat wounds and various types of scarring, primarily following surgery.
Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Eisai Co., Ltd. announced today that Eisai has received approval from “Science Based Targets Initiative” for Eisai’s mid and long-term targets for greenhouse gas reduction.
Probiodrug AG announced today its first quarter business update for the period ending March 31, 2019.
Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.
Promore Pharma AB (publ) publishes its Interim report for the first quarter 2019 at 13.00 CET on 21 May 2019.
GeoVax Labs, Inc. announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.
PRESS RELEASES